perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2019-64-6-11-19perinatology-1011Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSСовременный взгляд на лечение хронического гепатита С у детей и подростковA modern view on the treatment of chronic hepatitis C in children and adolescentshttps://orcid.org/0000-0002-5413-9599ВолынецГ. В.VolynetsG. V.

Волынец Галина Васильевна – д.м.н., гл. науч. сотр. отдела гастроэнтерологии Научно-исследовательского клинического института педиатрии им. академика Ю.Е. Вельтищева

Москва

Moscow

volynetsgv@gmail.comФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ОСП «Научно-исследовательский клинический институт педиатрии им. академика Ю.Е. Вельтищева» ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияPirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation; Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationRussian Federation2019150120206461119Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20202020Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/1011

Цель статьи – обобщающий обзор подходов к лечению инфекции, вызванной вирусом гепатита С (HCV), у детей и подростков. Статья посвящена вопросам, затрагивающим показания, противопоказания и оптимальные схемы лечения у детей и подростков с хронической HCV-инфекцией.

Во всем мире 13,2 (11,5–21,2) млн детей в возрасте от 1 до 15 лет инфицированы HCV. У детей, как правило, хроническая HCV-инфекция более вялотекущая, чем у взрослых; внепеченочные проявления преимущественно в виде субклинического гипотиреоза и аутоиммунного тиреоидита встречаются соответственно в 11 и 5,6% случаев. Риск развития цирроза печени у детей с хронической HCV-инфекцией составляет от 1 до 4%, в то время как мостовидный фиброз и тяжелое воспаление печени описаны примерно у 15%. В статье рассматриваются вопросы терапии: цели, конечные точки, показания, противопоказания и оптимальный режим лечения у детей с хронической HCV-инфекцией. Представлены рекомендации, сформулированные Европейским обществом детских гастроэнтерологов, гепатологов и нутрициологов (ESPGHAN).

Заключение. Хроническая HCV-инфекция у детей в целом протекает в доброкачественной форме, однако лечение заболевания требуется для достижения успеха в деле ликвидации гепатита С.

The purpose of the article is a summary overview of approaches to the treatment of infection caused by hepatitis C virus (HCV) in children and adolescents. The article is devoted to issues affecting indications, contraindications and optimal treatment regimens in children and adolescents with chronic HCV infection.

All over the world, 13

All over the world, 13.2 (11.5–21.2) million children aged 1–15 years have HCV. Chronic HCV infection in children, as a rule, is more lethargic than in adults; extrahepatic manifestations mainly in the form of subclinical hypothyroidism and autoimmune thyroiditis occur, respectively, in 11 and 5.6% of cases. The risk of developing liver cirrhosis in children with chronic HCV infection ranges from 1 to 4%, while bridging fibrosis and severe liver inflammation are described in approximately 15%. The article discusses the issues of therapy: goals, endpoints, indications, contraindications and the optimal treatment regimen in children with chronic HCV infection. The recommendations made by the European Society for Pediatric Gastroenterologists, Hepatologists and Nutritionists (ESPGHAN) are provided.

Conclusion

Conclusion. Chronic HCV infection in children in general is in a benign form, but treatment of the disease is required to achieve success in eliminating hepatitis C.

детивирус гепатита Слечениепротивовирусные препараты прямого действияchildrenhepatitis C virustreatmentdirect-acting antiviral drugsReferencesCacoub P., Gragnani L., Comarmond C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(5): 165–173. DOI: 10.1016/j.dld.2014.10.005Cacoub P., Gragnani L., Comarmond C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(5): 165–173. DOI: 10.1016/j.dld.2014.10.005Kanto T., Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006; 45(4): 183–191. DOI:10.2169/internalmedicine.45.1530Kanto T., Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006; 45(4): 183–191. DOI:10.2169/internalmedicine.45.1530Семенов А.В., Арсентьева Н.А., Елезов Д.С., Кондратьев И.В., Тотольян А.А. Особенности популяционного состава CXCRS-положительных лимфоцитов периферической крови больных хроническим гепатитом С. Журнал микробиологии, эпидемиологии и иммунобиологии 2013; 6: 69–76.Semenov A.V., Arsent’eva N.A., Elezov D.S., Kondrat’ev I.V., Totolian A.A. Features of population composition of peripheral blood CXCR3-positive lymphocytes in chronic viral hepatitis c patients. Zhurnal mikrobiologii, epidemiologii i immunobiologii 2013; 6: 69–76 (in Russ.)Cotte L., Cua E., Reynes J., Raffi F., Rey D., Delobel P., et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int 2018; published online June 30. DOI: 10.1111/liv.13922Cotte L., Cua E., Reynes J., Raffi F., Rey D., Delobel P., et al. Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. Liver Int 2018; published online June 30. DOI: 10.1111/liv.13922Platt L., Easterbrook P., Gower E., McDonald B., Sabin K., McGowan C. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16(7): 797–808. DOI:10.1016/S1473-3099(15)00485-5Platt L., Easterbrook P., Gower E., McDonald B., Sabin K., McGowan C. et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis 2016; 16(7): 797–808. DOI:10.1016/S1473-3099(15)00485-5van de Laar T., Pybus O., Bruisten S., Brown D., Nelson M., Bhagani S. et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterol 2009; 136(5): 1609–1617. DOI:10.1053/j.gastro.2009.02.006van de Laar T., Pybus O., Bruisten S., Brown D., Nelson M., Bhagani S. et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterol 2009; 136(5): 1609–1617. DOI:10.1053/j.gastro.2009.02.006Zibbell J.E., Iqbal K., Patel R.C., Suryaprasad A., Sanders K.J., Moore-Moravian L. et al. Centers for Disease Control and Prevention (CDC). Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 2015; 64(17): 453–458.Zibbell J.E., Iqbal K., Patel R.C., Suryaprasad A., Sanders K.J., Moore-Moravian L. et al. Centers for Disease Control and Prevention (CDC). Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years – Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012. MMWR Morb Mortal Wkly Rep 2015; 64(17): 453–458.WHO. Global hepatitis report 2017. World Health Organization. https://apps.who.int/iris/handle/10665/255016WHO. Global hepatitis report 2017. World Health Organization. https://apps.who.int/iris/handle/10665/255016Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11(1): 28–35. DOI: 10.1038/nrgastro.2013.179Thursz M., Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11(1): 28–35. DOI: 10.1038/nrgastro.2013.179Indolfi G., Azzari C., Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163(6): 1549–1552.e1. DOI:10.1016/j.jpeds.2013.06.077Indolfi G., Azzari C., Resti M. Perinatal transmission of hepatitis C virus. J Pediatr 2013; 163(6): 1549–1552.e1. DOI:10.1016/j.jpeds.2013.06.077Benova L., Mohamoud Y.A., Calvert C., Abu-Raddad L.J. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59(6): 765–73. DOI:10.1093/cid/ciu447Benova L., Mohamoud Y.A., Calvert C., Abu-Raddad L.J. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis 2014; 59(6): 765–73. DOI:10.1093/cid/ciu447European Paediatric Hepatitis C Virus Network. A significant sex–but not elective cesarean section–effect on mother-tochild transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872–1879.European Paediatric Hepatitis C Virus Network. A significant sex–but not elective cesarean section–effect on mother-tochild transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 1872–1879.Indolfi G., Nesi A., Resti M. Intrafamilial transmission of hepatitis C virus. J Med Virol 2013; 85(4): 608–614. DOI:10.1002/jmv.23522Indolfi G., Nesi A., Resti M. Intrafamilial transmission of hepatitis C virus. J Med Virol 2013; 85(4): 608–614. DOI:10.1002/jmv.23522Jafari S., Copes R., Baharlou S., Etminan M., Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010; 14(11): e928–40. DOI: 10.1016/j.ijid.2010.03.019Jafari S., Copes R., Baharlou S., Etminan M., Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis 2010; 14(11): e928–40. DOI: 10.1016/j.ijid.2010.03.019Global Burden of Disease Study 2013 Collaborators. Glo al, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743–800. DOI: 10.1016/S0140-6736(15)60692-4Global Burden of Disease Study 2013 Collaborators. Glo al, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(9995): 743–800. DOI: 10.1016/S0140-6736(15)60692-4El-Sayed M.H., Razavi H. Global estimate of HCV infection in the pediatric and adolescent population. J Hepatol 2015; 62(2): 831–832. DOI: 10.1016/S0168-8278(15)31458-6El-Sayed M.H., Razavi H. Global estimate of HCV infection in the pediatric and adolescent population. J Hepatol 2015; 62(2): 831–832. DOI: 10.1016/S0168-8278(15)31458-6Razavi H., El-Sayed M. Updated global estimate of HCV infection in the pediatric population. 2016. http://cdafound.org/content/Downloads/Pediatric%20Prevalence%20161201.pdf (accessed March 31, 2019).Razavi H., El-Sayed M. Updated global estimate of HCV infection in the pediatric population. 2016. http://cdafound.org/content/Downloads/Pediatric%20Prevalence%20161201.pdf (accessed March 31, 2019).Delgado-Borrego A., Smith L., Jonas M.M., Hall C.A., Negre B., Jordan S.H. et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161(5): 915–921. DOI: 10.1016/j.jpeds.2012.05.002Delgado-Borrego A., Smith L., Jonas M.M., Hall C.A., Negre B., Jordan S.H. et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161(5): 915–921. DOI: 10.1016/j.jpeds.2012.05.002Koneru A., Nelson N., Hariri S., Canary L., Sanders K.J., Maxwell J.F. et al. Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission – United States and Kentucky, 2011–2014. MMWR Morb Mortal Wkly Rep 2016; 65(28): 705–710.Koneru A., Nelson N., Hariri S., Canary L., Sanders K.J., Maxwell J.F. et al. Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission – United States and Kentucky, 2011–2014. MMWR Morb Mortal Wkly Rep 2016; 65(28): 705–710.United Nations. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015. https://www.preventionweb.net/go/45418United Nations. Transforming our world: the 2030 agenda for sustainable development. New York: United Nations, 2015. https://www.preventionweb.net/go/45418Bortolotti F., Verucchi G., Camma` C., Cabibo G., Zancan L., Indolfi G. et al. Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease. Gastroenterol 2008; 134: 1900–1907. DOI: 10.1053/j.gastro.2008.02.082Bortolotti F., Verucchi G., Camma` C., Cabibo G., Zancan L., Indolfi G. et al. Long-Term Course of Chronic Hepatitis C in Children: From Viral Clearance to End-Stage Liver Disease. Gastroenterol 2008; 134: 1900–1907. DOI: 10.1053/j.gastro.2008.02.082Resti M., Jara P., Hierro L., Azzari C., Giacchino R., Zuin G. et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70: 373–377. DOI: 10.1002/jmv.10405Resti M., Jara P., Hierro L., Azzari C., Giacchino R., Zuin G. et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J Med Virol 2003; 70: 373–377. DOI: 10.1002/jmv.10405Network EPHCV. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 45–51. DOI: 10.1086/430601Network EPHCV. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41: 45–51. DOI: 10.1086/430601Garazzino S., Calitri C., Versace A., Alfarano A., Scolfaro C., Bertaina C. et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014; 173(8): 1025–1031. DOI: 10.1007/s00431-014-2286-6Garazzino S., Calitri C., Versace A., Alfarano A., Scolfaro C., Bertaina C. et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr 2014; 173(8): 1025–1031. DOI: 10.1007/s00431-014-2286-6Jara P., Resti M., Hierro L., Giacchino R., Barbera C., Zancan L. et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275–280. DOI: 10.1086/345908Jara P., Resti M., Hierro L., Giacchino R., Barbera C., Zancan L. et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36: 275–280. DOI: 10.1086/345908Cacoub P., Gragnani L., Comarmond C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(5): 165–173. DOI: 10.1016/j.dld.2014.10.005Cacoub P., Gragnani L., Comarmond C., Zignego A.L. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(5): 165–173. DOI: 10.1016/j.dld.2014.10.005Indolfi G., Stagi S., Bartolini E., Salti R., de Martino M., Azzari C., Resti M. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) 2008; 68: 117–121. DOI: 10.1111/j.1365-2265.2007.03009.xIndolfi G., Stagi S., Bartolini E., Salti R., de Martino M., Azzari C., Resti M. Thyroid function and anti-thyroid autoantibodies in untreated children with vertically acquired chronic hepatitis C virus infection. Clin Endocrinol (Oxf) 2008; 68: 117–121. DOI: 10.1111/j.1365-2265.2007.03009.xGoodman Z.D., Makhlouf H.R., Liu L., Balistreri W., Gonzalez-Peralta R.P., Haber B. et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836–843. DOI: 10.1002/hep.22094Goodman Z.D., Makhlouf H.R., Liu L., Balistreri W., Gonzalez-Peralta R.P., Haber B. et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836–843. DOI: 10.1002/hep.22094Harris H.E., Mieli-Vergani G., Kelly D., Davison S., Gibb D.M., Ramsay M.E.; HCV National Register Steering Group. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45(3): 335–341. DOI: 10.1097/MPG.0b013e3180dc9337Harris H.E., Mieli-Vergani G., Kelly D., Davison S., Gibb D.M., Ramsay M.E.; HCV National Register Steering Group. A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease. J Pediatr Gastroenterol Nutr 2007; 45(3): 335–341. DOI: 10.1097/MPG.0b013e3180dc9337Iorio R., Giannattasio A., Sepe A., Terracciano L.M., Vecchione R., Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41(10): 1431–7. DOI:10.1086/497141Iorio R., Giannattasio A., Sepe A., Terracciano L.M., Vecchione R., Vegnente A. Chronic hepatitis C in childhood: an 18-year experience. Clin Infect Dis 2005; 41(10): 1431–7. DOI:10.1086/497141Mohan P., Barton B.A., Narkewicz M.R., Molleston J.P., Gonzalez-Peralta R.P., Rosenthal P. et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C – a retrospective study. Hepatology 2013; 58(5): 1580–1586. DOI: 10.1002/hep.26519Mohan P., Barton B.A., Narkewicz M.R., Molleston J.P., Gonzalez-Peralta R.P., Rosenthal P. et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C – a retrospective study. Hepatology 2013; 58(5): 1580–1586. DOI: 10.1002/hep.26519González-Peralta R.P., Langham M.R.Jr., Andres J.M., Mohan P., Colombani P.M., Alford M.K., Schwarz K.B. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48(5): 630–635. DOI: 10.1097/MPG.0b013e318170af04González-Peralta R.P., Langham M.R.Jr., Andres J.M., Mohan P., Colombani P.M., Alford M.K., Schwarz K.B. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48(5): 630–635. DOI: 10.1097/MPG.0b013e318170af04Malik S., Dekio F., Wen J.W. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplant 2014; 18(2): E64–68. DOI:10.1111/petr.12223Malik S., Dekio F., Wen J.W. Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir. Pediatr Transplant 2014; 18(2): E64–68. DOI:10.1111/petr.12223Modin L., Arshad A., Wilkes B., Benselin J., Lloyd C., Irving W.L., Kelly D.A. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019; 70(3): 371–378. DOI: 10.1016/j.jhep.2018.11.013Modin L., Arshad A., Wilkes B., Benselin J., Lloyd C., Irving W.L., Kelly D.A. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019; 70(3): 371–378. DOI: 10.1016/j.jhep.2018.11.013EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66(1): 153–194. DOI: 10.1016/j.jhep.2016.09.001EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66(1): 153–194. DOI: 10.1016/j.jhep.2016.09.001Omata M., Kanda T., Wei L., Yu M.L., Chuang W.L., Ibrahim A. et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016; 10(5): 702–726. DOI: 10.1007/s12072-016-9717-6Omata M., Kanda T., Wei L., Yu M.L., Chuang W.L., Ibrahim A. et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016; 10(5): 702–726. DOI: 10.1007/s12072-016-9717-6Wirth S., Rosenthal P., Gonzalez-Peralta R.P., Jonas M.M., Balistreri W.F., Lin C.H. et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017; 66(4): 1102–1110. DOI:10.1002/hep.29278Wirth S., Rosenthal P., Gonzalez-Peralta R.P., Jonas M.M., Balistreri W.F., Lin C.H. et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017; 66(4): 1102–1110. DOI:10.1002/hep.29278Younossi Z.M., Stepanova M., Schwarz K.B., Wirth S., Rosenthal P., Gonzalez-Peralta R. et al. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat 2018; 25(4): 354–362. DOI: 10.1111/jvh.12830Younossi Z.M., Stepanova M., Schwarz K.B., Wirth S., Rosenthal P., Gonzalez-Peralta R. et al. Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin. J Viral Hepat 2018; 25(4): 354–362. DOI: 10.1111/jvh.12830Younossi Z.M., Stepanova M., Balistreri W., Schwarz K., Murray K.F., Rosenthal P. et al. Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. J Pediatr Gastroenterol Nutr 2018; 66(1): 112–116. DOI: 10.1097/MPG.0000000000001754Younossi Z.M., Stepanova M., Balistreri W., Schwarz K., Murray K.F., Rosenthal P. et al. Health-related Quality of Life in Adolescent Patients With Hepatitis C Genotype 1 Treated With Sofosbuvir and Ledipasvir. J Pediatr Gastroenterol Nutr 2018; 66(1): 112–116. DOI: 10.1097/MPG.0000000000001754Balistreri W.F., Murray K.F., Rosenthal P., Bansal S., Lin C.H., Kersey K. et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66(2): 371–378. DOI: 10.1002/hep.28995Balistreri W.F., Murray K.F., Rosenthal P., Bansal S., Lin C.H., Kersey K. et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66(2): 371–378. DOI: 10.1002/hep.28995AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018; 67(10): 1477–1492. DOI: 10.1093/cid/ciy585AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2018; 67(10): 1477–1492. DOI: 10.1093/cid/ciy585European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69(2): 461–511. DOI: 10.1016/j.jhep.2018.03.026European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69(2): 461–511. DOI: 10.1016/j.jhep.2018.03.026WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization, 2018; 108.WHO. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization, 2018; 108.Indolfi G., Hierro L., Dezsofi A., Jahnel J., Debray D., Hadzic N. et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66(3): 505–515. DOI: 10.1097/MPG.0000000000001872Indolfi G., Hierro L., Dezsofi A., Jahnel J., Debray D., Hadzic N. et al. Treatment of Chronic Hepatitis C Virus Infection in Children: A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66(3): 505–515. DOI: 10.1097/MPG.0000000000001872El-Khayat H.R., Kamal E.M., El-Sayed M.H., El-Shabrawi M., Ayoub H., RizK A. et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther 2018; 47(6): 838–844. DOI: 10.1111/apt.14502El-Khayat H.R., Kamal E.M., El-Sayed M.H., El-Shabrawi M., Ayoub H., RizK A. et al. The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. Aliment Pharmacol Ther 2018; 47(6): 838–844. DOI: 10.1111/apt.14502El-Karaksy H., Mogahed E.A., Abdullatif H., Ghobrial C., El-Raziky M.S., El-Koofy N. et al. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. J Pediatr Gastroenterol Nutr 2018; 67(5): 626–630. DOI: 10.1097/MPG.0000000000002101El-Karaksy H., Mogahed E.A., Abdullatif H., Ghobrial C., El-Raziky M.S., El-Koofy N. et al. Sustained Viral Response in Genotype 4 Chronic Hepatitis C Virus-infected Children and Adolescents Treated With Sofosbuvir/Ledipasvir. J Pediatr Gastroenterol Nutr 2018; 67(5): 626–630. DOI: 10.1097/MPG.0000000000002101Jonas M.M., Squires R.H., Rhee S.M., Lin C.W., Bessho K., Feiterna-Sperling C. et al. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Patients with Genotypes 1–6 Chronic HCV Infection: Part 1 of the Dora Study. Hepatology 2018; 68(suppl): 1347A–1348A.Jonas M.M., Squires R.H., Rhee S.M., Lin C.W., Bessho K., Feiterna-Sperling C. et al. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Patients with Genotypes 1–6 Chronic HCV Infection: Part 1 of the Dora Study. Hepatology 2018; 68(suppl): 1347A–1348A.Leung D.H., Wirth S., Yao B.B., Viani R.M., Gonzalez-Peralta R.P., Jonas M.M. et al. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. Hepatol Commun 2018; 2(11): 1311–1319. DOI: 10.1002/hep4.1250Leung D.H., Wirth S., Yao B.B., Viani R.M., Gonzalez-Peralta R.P., Jonas M.M. et al. Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4. Hepatol Commun 2018; 2(11): 1311–1319. DOI: 10.1002/hep4.1250El-Sayed M., Hassany M., Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection. J Hepatol 2017; 66(suppl): 178. DOI:10.1016/S0168-8278(17)30642-6El-Sayed M., Hassany M., Asem N. A pilot study for safety and efficacy of 12 weeks sofosbuvir plus daclatasvir with or without ribavirin in egyptian adolescents with chronic hepatitis C virus Infection. J Hepatol 2017; 66(suppl): 178. DOI:10.1016/S0168-8278(17)30642-6El-Shabrawi M.H., Abdo A.M., El-Khayat H.R., Yakoot M. Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr 2018; 66(3): 425–427. DOI: 10.1097/MPG.0000000000001838El-Shabrawi M.H., Abdo A.M., El-Khayat H.R., Yakoot M. Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr 2018; 66(3): 425–427. DOI: 10.1097/MPG.0000000000001838Yakoot M., El-Shabrawi M.H., AbdElgawad M.M., Mahfouz A.A., Helmy S., Abdo A.M., El-Khayat H.R. Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr 2018; 67(1): 86–89. DOI: 10.1097/MPG.0000000000001968Yakoot M., El-Shabrawi M.H., AbdElgawad M.M., Mahfouz A.A., Helmy S., Abdo A.M., El-Khayat H.R. Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients With Chronic Hepatitis C Infection. J Pediatr Gastroenterol Nutr 2018; 67(1): 86–89. DOI: 10.1097/MPG.0000000000001968Al Ali J., Owayed S., Al-Qabandi W., Husain K., Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9(2): 156–160.Al Ali J., Owayed S., Al-Qabandi W., Husain K., Hasan F. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010; 9(2): 156–160.Turkova A., Giacomet V., Goetghebuer T., Miloenko M., Nicolini L.A., Noguera-Julian A. et al. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad 2015; 1(3): 179–184.Turkova A., Giacomet V., Goetghebuer T., Miloenko M., Nicolini L.A., Noguera-Julian A. et al. HCV treatment in children and young adults with HIV/HCV co-infection in Europe. J Virus Erad 2015; 1(3): 179–184.Druyts E., Thorlund K., Wu P., Kanters S., Yaya S., Cooper C.L., Mills E.J. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56(7): 961–967. DOI: 10.1093/cid/cis1031Druyts E., Thorlund K., Wu P., Kanters S., Yaya S., Cooper C.L., Mills E.J. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013; 56(7): 961–967. DOI: 10.1093/cid/cis1031Mack C.L., Gonzalez-Peralta R.P., Gupta N., Leung D., Narkewicz M.R., Roberts E.A. et al. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54(6): 838–855. DOI: 10.1097/MPG.0b013e318258328dMack C.L., Gonzalez-Peralta R.P., Gupta N., Leung D., Narkewicz M.R., Roberts E.A. et al. NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr 2012; 54(6): 838–855. DOI: 10.1097/MPG.0b013e318258328dRosenthal P., Schwarz K.B., Gonzalez-Peralta R.P., Lin C.H., Kelly D.A., Nightingale S. et al. Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology. 2019 Jun 20. DOI: 10.1002/hep.30821Rosenthal P., Schwarz K.B., Gonzalez-Peralta R.P., Lin C.H., Kelly D.A., Nightingale S. et al. Sofosbuvir and Ribavirin Therapy for Children 3 to <12 Years Old With Hepatitis C Virus Genotype 2 or 3 Infection. Hepatology. 2019 Jun 20. DOI: 10.1002/hep.30821Murray K.F., Balistreri W.F., Bansal S., Whitworth S., Evans H.M., Gonzalez-Peralta R.P. et al. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6–11. Hepatology 2018; 68(6): 2158–2166. DOI: 10.1002/hep.30123Murray K.F., Balistreri W.F., Bansal S., Whitworth S., Evans H.M., Gonzalez-Peralta R.P. et al. Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6–11. Hepatology 2018; 68(6): 2158–2166. DOI: 10.1002/hep.30123Garrison K.L., Mathias A., Kersey K., Kanwar B., Ni L., Jain A. et al. Pharmacokinetics of once-daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-infected pediatrics aged 6 to <12 years old. Hepatology 2016; 64 (suppl):436A.Garrison K.L., Mathias A., Kersey K., Kanwar B., Ni L., Jain A. et al. Pharmacokinetics of once-daily Sofosbuvir and Ledipasvir/Sofosbuvir in HCV-infected pediatrics aged 6 to <12 years old. Hepatology 2016; 64 (suppl):436A.El-Shabrawi M.H.F., Kamal N.M., El-Khayat H.R., Kamal E.M., AbdElgawad M.M., Yakoot M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6to 12-year old children. Aliment Pharmacol Ther 2018; 47(12): 1699–1704. DOI: 10.1111/apt.14677El-Shabrawi M.H.F., Kamal N.M., El-Khayat H.R., Kamal E.M., AbdElgawad M.M., Yakoot M. A pilot single arm observational study of sofosbuvir/ledipasvir (200 + 45 mg) in 6to 12-year old children. Aliment Pharmacol Ther 2018; 47(12): 1699–1704. DOI: 10.1111/apt.14677

The authors declare that there are no conflicts of interest present.